| TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
|
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) |
|
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML |
|
Aging |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia |
|
Critical reviews in hematology/oncology |
Myelodysplastic Syndromes (MDS) |
| Eat and be healthy: nutritional status in myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse |
|
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
